SCOPUS 정보 검색 플랫폼

Clinical Oncology

Volumn 18, Issue 8, 2006, Pages 635-

Prevalence of Mutation in the Epidermal Growth Factor Receptor Gene in Chinese Patients with Non-small Cell Lung Cancer

(8) Jiang, B a Zhu, Z Z b Liu, F a Hou, L F c Gu, J d Chen, E d Tzeng, C M d Zhu, G d

a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE (China)

b No 113 Hospital of People's Liberation Army (China)

c NATIONAL CANCER INSTITUTE (United States)

d Shanghai GeneCore Biotechnologies Co (China)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB; K RAS PROTEIN;

ADULT; AGE DISTRIBUTION; AGED; CANCER PATIENT; CHINESE; CIGARETTE SMOKING; CONTROLLED STUDY; DNA SEQUENCE; EXON; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; LARGE CELL CARCINOMA; LETTER; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL DOCUMENTATION; MUTATIONAL ANALYSIS; PREVALENCE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RECEPTOR GENE; SEX DIFFERENCE; SQUAMOUS CELL CARCINOMA;

CARCINOMA, NON-SMALL-CELL LUNG; CHINA; FEMALE; GENES, ERBB-1; GENES, RAS; HUMANS; LUNG NEOPLASMS; MALE; MUTATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; SMOKING;

EID: 33748207280 PISSN: 09366555 EISSN: None Source Type: Journal
DOI: 10.1016/j.clon.2006.06.001 Document Type: Letter

Times cited : (1)

References (5)

1
- 2342471392
- Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
- Lynch T.J., Bell D.W., Sordella R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350 (2004) 2129-2139
- (2004) N Engl J Med , vol.350 , pp. 2129-2139
- Lynch, T.J.¹ Bell, D.W.² Sordella, R.³

2
- 2342624080
- EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy
- Paez J.G., Janne P.A., Lee J.C., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 (2004) 1497-1500
- (2004) Science , vol.304 , pp. 1497-1500
- Paez, J.G.¹ Janne, P.A.² Lee, J.C.³

3
- 15744372810
- KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib
- Pao W., Wang T.Y., Riely G.J., et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2 (2005) e17
- (2005) PLoS Med , vol.2
- Pao, W.¹ Wang, T.Y.² Riely, G.J.³

4
- 23844517762
- The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced non-small-cell lung cancer
- Zhang X.T., Li L.Y., Mu X.L., et al. The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced non-small-cell lung cancer. Ann Oncol 16 (2005) 1334-1342
- (2005) Ann Oncol , vol.16 , pp. 1334-1342
- Zhang, X.T.¹ Li, L.Y.² Mu, X.L.³

5
- 19944426858
- High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan
- Huang S.F., Liu H.P., Li L.H., et al. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res 10 (2004) 8195-8203
- (2004) Clin Cancer Res , vol.10 , pp. 8195-8203
- Huang, S.F.¹ Liu, H.P.² Li, L.H.³

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.